MA41988B1 - Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa - Google Patents
Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampaInfo
- Publication number
- MA41988B1 MA41988B1 MA41988A MA41988A MA41988B1 MA 41988 B1 MA41988 B1 MA 41988B1 MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A MA 41988 B1 MA41988 B1 MA 41988B1
- Authority
- MA
- Morocco
- Prior art keywords
- azabenzimidazoles
- receptor modulators
- ampa receptor
- compounds
- formula
- Prior art date
Links
- 102000003678 AMPA Receptors Human genes 0.000 title 1
- 108090000078 AMPA Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention porte sur des composés de formule (l) et sur leurs sels, n-oxydes et solvates, de qualité pharmaceutique. L'invention concerne également des compositions pharmaceutiques comprenant des composés de formule (i), et des méthodes d'utilisation de ces composés de formule (i).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154313P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/029801 WO2016176460A1 (fr) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles et leur utilisation en tant que modulateurs des récepteurs ampa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41988A MA41988A (fr) | 2018-07-03 |
| MA41988B1 true MA41988B1 (fr) | 2021-03-31 |
Family
ID=56008859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41988A MA41988B1 (fr) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US11312712B2 (fr) |
| EP (3) | EP3901153A1 (fr) |
| JP (2) | JP6800886B2 (fr) |
| KR (2) | KR20170140382A (fr) |
| CN (1) | CN107835814B (fr) |
| AR (1) | AR104447A1 (fr) |
| AU (2) | AU2016255434C1 (fr) |
| BR (2) | BR122023023802A2 (fr) |
| CA (1) | CA2983826A1 (fr) |
| CO (1) | CO2017011017A2 (fr) |
| CR (1) | CR20170484A (fr) |
| CY (1) | CY1124059T1 (fr) |
| DK (1) | DK3288940T5 (fr) |
| EA (1) | EA033281B1 (fr) |
| EC (1) | ECSP17074645A (fr) |
| ES (1) | ES2865330T3 (fr) |
| GT (1) | GT201700231A (fr) |
| HK (1) | HK1252249A1 (fr) |
| HR (1) | HRP20210403T1 (fr) |
| HU (1) | HUE053943T2 (fr) |
| IL (1) | IL254848B (fr) |
| JO (1) | JO3654B1 (fr) |
| LT (1) | LT3288940T (fr) |
| MA (1) | MA41988B1 (fr) |
| MD (1) | MD3288940T2 (fr) |
| MX (1) | MX2017013886A (fr) |
| MY (1) | MY194104A (fr) |
| NI (1) | NI201700129A (fr) |
| PH (1) | PH12017501816A1 (fr) |
| PL (1) | PL3288940T3 (fr) |
| PT (1) | PT3288940T (fr) |
| RS (1) | RS61688B1 (fr) |
| SG (1) | SG11201708190UA (fr) |
| SI (1) | SI3288940T1 (fr) |
| TW (1) | TWI706952B (fr) |
| UA (1) | UA120304C2 (fr) |
| UY (1) | UY36654A (fr) |
| WO (1) | WO2016176460A1 (fr) |
| ZA (1) | ZA201708065B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016255431B2 (en) * | 2015-04-29 | 2020-05-07 | Janssen Pharmaceutica Nv | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators |
| CN107383004B (zh) * | 2017-07-05 | 2020-04-17 | 浙江大学 | 2-氨基咪唑并吡啶类衍生物及制备和应用 |
| EP3679027A1 (fr) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| US11447488B2 (en) | 2017-10-06 | 2022-09-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| KR20210125471A (ko) | 2018-10-05 | 2021-10-18 | 안나푸르나 바이오, 인코포레이티드 | Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 |
| CA3118218A1 (fr) * | 2018-10-30 | 2020-05-07 | Repare Therapeutics Inc. | Composes, compositions pharmaceutiques, procedes de preparation de composes et leur utilisation en tant qu'inhibiteurs de kinase atr |
| WO2021012049A1 (fr) * | 2019-07-22 | 2021-01-28 | Repare Therapeutics Inc. | Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
| CN115304599A (zh) * | 2022-09-20 | 2022-11-08 | 浙大宁波理工学院 | 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
| CN1051313A (zh) | 1990-11-07 | 1991-05-15 | 鞍山市振东工业尼龙厂 | 尼龙球磨罐及其热装工艺 |
| GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| TW251284B (fr) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| AU685881B2 (en) * | 1994-02-10 | 1998-01-29 | Pfizer Inc. | 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists |
| US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| UA54403C2 (uk) | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
| DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
| JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
| EP1139754A4 (fr) | 1998-12-31 | 2002-12-18 | Sugen Inc | Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| AU2001282865A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives |
| US6548576B1 (en) | 2001-11-07 | 2003-04-15 | Bourns, Inc. | Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| CA2576765C (fr) * | 2004-09-03 | 2013-05-28 | Applied Research Systems Ars Holding N.V. | Azolidinones de methylene de pyridine et inhibiteurs de la phosphoinositide |
| KR20130091791A (ko) | 2005-09-30 | 2013-08-19 | 글락소 그룹 리미티드 | Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도 |
| WO2007135529A2 (fr) | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Composés d'azabenzimidazolyle |
| EP2086643B1 (fr) | 2006-11-03 | 2011-03-23 | Glaxo Group Limited | Composés de potentialisation du récepteur ampa et utilisations en médecine |
| WO2008113795A1 (fr) | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Composés potentialisant le récepteur ampa et leurs utilisations en médecine |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009067607A2 (fr) | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinaisons d'inhibiteurs de pde4 et d'antipsychotiques pour le traitement de troubles psychotiques |
| US8450343B2 (en) * | 2007-12-06 | 2013-05-28 | Xianhai Huang | Gamma secretase modulators |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| WO2010005528A2 (fr) * | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Dérivés acide carboxylique de pyrrolopyridine |
| GB0822425D0 (en) | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2011056985A2 (fr) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Composés hétérocycliques substitués |
| WO2011156245A2 (fr) * | 2010-06-09 | 2011-12-15 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs de mglur2 |
| WO2012020848A1 (fr) | 2010-08-10 | 2012-02-16 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et son utilisation |
| WO2012021382A1 (fr) | 2010-08-12 | 2012-02-16 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs de mglur2 |
| US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013130501A1 (fr) * | 2012-03-01 | 2013-09-06 | The Board Of Regents Of The University Of Texas System | Modulateurs bivalents allostériques positifs des récepteurs ampa |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| JO3225B1 (ar) | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| PE20151332A1 (es) | 2013-02-19 | 2015-09-20 | Pfizer | Compuestos de azabencimidazol |
-
2016
- 2016-04-28 SG SG11201708190UA patent/SG11201708190UA/en unknown
- 2016-04-28 EA EA201792374A patent/EA033281B1/ru unknown
- 2016-04-28 PT PT167232040T patent/PT3288940T/pt unknown
- 2016-04-28 KR KR1020177034350A patent/KR20170140382A/ko active Application Filing
- 2016-04-28 EP EP21157913.1A patent/EP3901153A1/fr active Pending
- 2016-04-28 DK DK16723204.0T patent/DK3288940T5/da active
- 2016-04-28 UA UAA201711635A patent/UA120304C2/uk unknown
- 2016-04-28 EP EP22200371.7A patent/EP4144736A1/fr active Pending
- 2016-04-28 MA MA41988A patent/MA41988B1/fr unknown
- 2016-04-28 CN CN201680038830.0A patent/CN107835814B/zh active Active
- 2016-04-28 KR KR1020247003619A patent/KR20240017991A/ko active Application Filing
- 2016-04-28 JO JOP/2016/0085A patent/JO3654B1/ar active
- 2016-04-28 PL PL16723204T patent/PL3288940T3/pl unknown
- 2016-04-28 BR BR122023023802-8A patent/BR122023023802A2/pt not_active Application Discontinuation
- 2016-04-28 AU AU2016255434A patent/AU2016255434C1/en active Active
- 2016-04-28 LT LTEP16723204.0T patent/LT3288940T/lt unknown
- 2016-04-28 BR BR112017023147-6A patent/BR112017023147B1/pt active IP Right Grant
- 2016-04-28 WO PCT/US2016/029801 patent/WO2016176460A1/fr active Application Filing
- 2016-04-28 AR ARP160101217A patent/AR104447A1/es unknown
- 2016-04-28 TW TW105113298A patent/TWI706952B/zh active
- 2016-04-28 RS RS20210362A patent/RS61688B1/sr unknown
- 2016-04-28 JP JP2017556634A patent/JP6800886B2/ja active Active
- 2016-04-28 CR CR20170484A patent/CR20170484A/es unknown
- 2016-04-28 UY UY0001036654A patent/UY36654A/es active IP Right Grant
- 2016-04-28 MY MYPI2017703998A patent/MY194104A/en unknown
- 2016-04-28 SI SI201631171T patent/SI3288940T1/sl unknown
- 2016-04-28 MX MX2017013886A patent/MX2017013886A/es active IP Right Grant
- 2016-04-28 EP EP16723204.0A patent/EP3288940B9/fr active Active
- 2016-04-28 CA CA2983826A patent/CA2983826A1/fr active Pending
- 2016-04-28 HU HUE16723204A patent/HUE053943T2/hu unknown
- 2016-04-28 ES ES16723204T patent/ES2865330T3/es active Active
- 2016-04-28 US US15/569,299 patent/US11312712B2/en active Active
- 2016-04-28 MD MDE20180234T patent/MD3288940T2/ro unknown
-
2017
- 2017-10-02 IL IL254848A patent/IL254848B/en active IP Right Grant
- 2017-10-03 PH PH12017501816A patent/PH12017501816A1/en unknown
- 2017-10-27 GT GT201700231A patent/GT201700231A/es unknown
- 2017-10-27 CO CONC2017/0011017A patent/CO2017011017A2/es unknown
- 2017-10-27 NI NI201700129A patent/NI201700129A/es unknown
- 2017-11-10 EC ECIEPI201774645A patent/ECSP17074645A/es unknown
- 2017-11-28 ZA ZA2017/08065A patent/ZA201708065B/en unknown
-
2018
- 2018-09-06 HK HK18111488.6A patent/HK1252249A1/zh unknown
-
2020
- 2020-07-30 AU AU2020210231A patent/AU2020210231B2/en active Active
- 2020-11-25 JP JP2020195323A patent/JP7026194B2/ja active Active
-
2021
- 2021-03-09 HR HRP20210403TT patent/HRP20210403T1/hr unknown
- 2021-04-23 CY CY20211100354T patent/CY1124059T1/el unknown
- 2021-05-19 US US17/324,520 patent/US20210284641A1/en active Pending
-
2022
- 2022-10-17 US US17/967,483 patent/US20230110576A1/en active Pending
- 2022-10-17 US US17/967,508 patent/US20230114165A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41988B1 (fr) | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| BR112015018508A2 (pt) | moduladores de enzimas modificadoras de metila, suas composições e uso | |
| MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
| GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| EA033197B1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
| EA201992679A1 (ru) | N-замещенные индольные производные | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| EA201892264A1 (ru) | Производные тетрагидроизохинолина | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| WO2013006308A3 (fr) | Dihydropyrazoles | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PH12016500312A1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| TR201908151T4 (tr) | İzoindolin türevleri. | |
| EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
| MX2017013885A (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| FR3022245B1 (fr) | Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation | |
| EA202192092A3 (ru) | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |